ClinicalTrials.gg
CompletedNCT01719380Updated Jun 23, 2021Results posted

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

A Phase 2 interventional study of LGX818 and Cetuximab in Colorectal Cancer, sponsored by Pfizer. Completed at 52 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-23.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing encorafenib in Colorectal Neoplasms — 5 open to participants now, 8 under way, 1 of them phase 3. encorafenib · Colorectal Neoplasms.

Enrollment
3rd of 16
156 · median 95
Started
2012
the only one that year
Phase 2
9 of 16
4 open now
Registered
2nd of 16
by date
Lead sponsor
5 of 16
Pfizer

Among the 16 studies testing encorafenib in Colorectal Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2012, is one of 9 in phase 2, and was the 2nd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

5 of the 16 studies testing encorafenib in Colorectal Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About encorafenib

encorafenib: first FDA approval 2018 (BRAFTOVI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing encorafenib in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Open-label dose escalation
  • BRAF inhibitor
  • LGX818
  • PI3K inhibitor
  • BYL719
  • EGFR
  • cetuximab
  • metastatic colorectal cancer
  • KRAS
  • BRAF
  • V600
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • colorectal cancer
  • Progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens
  • ≥ 3 months
  • performance status ≤ 2

Exclusion criteria

Exclusion Criteria:

  • Symptomatic or untreated
  • Symptomatic
  • Patients with clinically manifested diabetes
  • Acute or chronic pancreatitis
  • cardiac disease

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    LGX818 + cetuximab

    Drug: LGX818 · Drug: Cetuximab

  • Experimental
    LGX818 + BYL719 + cetuximab

    Drug: LGX818 · Drug: Cetuximab · Drug: BYL719

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants With Incidence of Dose Limiting Toxicities (DLTs): Cycle 1

    DLTs were defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first 28 days of treatment and meets any of the criteria included blood and lymphatic system disorders, investigations (blood, renal, hepatic, metabolic), skin and subcutaneous tissue disorders: rash, HFSR (hand foot skin reaction) and/or photosensitivity, metabolism and nutrition disorders: hyperglycemia, gastrointestinal disorders, cardiac disorders, vascular disorders, general disorders and administration site conditions, tumor lysis syndrome, ophthalmologic and other adverse events: study drug-related fever, alkaline phosphatase elevation.

    Time frame: Cycle 1: Day 1 to Day 28

  2. Phase 2: Progression Free Survival (PFS)

    PFS was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause. Participants who did not progress per RECIST (Response Evaluation Criteria in Solid Tumors) version (v) 1.1, were not known to have died prior to the data cut-off, or received any further anticancer therapy were censored at the date of last adequate tumor assessment or the anticancer therapy date, whichever was earlier.

    Time frame: From the date of randomization until the first documentation of disease progression or death due to any cause, censored date, whichever occurred first (maximum up to 43 months)

Secondary outcomes

  1. Number of Participants With Treatment - Emergent Adverse Events of Grade 3 or 4 Severity Based on National Cancer Institute of Common Terminology Criteria (NCI-CTCAE), Version 4.0

    An AE was any untoward medical occurrence attributed to study drug in participants who received study drug. As per NCI-CTCAE v4.0, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to study drug. Treatment-emergent AEs are between first dose of study drug and up to 30 days after last dose of study drug, that were absent before treatment or that worsened relative to pretreatment state. Number of participants with any Grade 3 or 4 treatment-emergent AE were reported in this outcome measure.

    Time frame: From screening up to 30 days after the last dose of study treatment (for a maximum duration of 43 months, approximately)

  2. Apparent Total Plasma Clearance (CL/F) of LGX818 (Encorafenib)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  3. Apparent Total Plasma Clearance at Steady State (CL/F, ss) of LGX818 (Encorafenib)

    Clearance of a drug at steady state is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  4. Apparent Total Plasma Clearance (CL/F) of BYL719 (Alpelisib)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  5. Apparent Total Plasma Clearance at Steady State (CL/F, ss) of BYL719 (Alpelisib)

    Clearance of a drug at steady state is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  6. Apparent Terminal Volume of Distribution (Vz/F) of LGX818 (Encorafenib)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  7. Apparent Terminal Volume of Distribution at Steady State (Vz/F, ss) of LGX818 (Encorafenib)

    Volume of distribution at steady state is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F, ss) is influenced by the fraction absorbed.

    Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  8. Apparent Terminal Volume of Distribution (Vz/F) of BYL719 (Alpelisib)

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  9. Apparent Terminal Volume of Distribution at Steady State (Vz/F, ss) of BYL719 (Alpelisib)

    Volume of distribution at steady state was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F, ss) is influenced by the fraction absorbed.

    Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  10. Time to Reach Maximum Observed Plasma Concentration (Tmax) of LGX818 (Encorafenib)

    Tmax was defined as the time to reach maximum observed plasma concentration of encorafenib.

    Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  11. Time to Reach Maximum Plasma Concentration at Steady State (Tmax, ss) of LGX818 (Encorafenib)

    Tmax, ss was defined as the time to reach maximum observed plasma concentration of LGX818 (encorafenib) at steady state.

    Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  12. Time to Reach Maximum Observed Plasma Concentration (Tmax) of BYL719 (Alpelisib)

    Tmax was defined as the time to reach maximum observed plasma concentration of alpelisib.

    Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  13. Time to Reach Maximum Plasma Concentration at Steady State (Tmax, ss) of BYL719 (Alpelisib)

    Tmax, ss was defined as the time to reach maximum observed plasma concentration of BYL719 (alpelisib) at steady state.

    Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  14. Time of Last Observed Plasma Concentration (T-last) of LGX818 (Encorafenib)

    T-last was defined as the time to reach last observed plasma concentration of encorafenib.

    Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  15. Time of Last Observed Plasma Concentration at Steady State (T-last, ss) of LGX818 (Encorafenib)

    T-last, ss was defined as the time to reach last observed plasma concentration of encorafenib at steady state.

    Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  16. Time of Last Observed Plasma Concentration (T-last) of BYL719 (Alpelisib)

    T-last was defined as the time to reach last observed plasma concentration of alpelisib.

    Time frame: Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  17. Time of Last Observed Plasma Concentration at Steady State (T-last, ss) of BYL719 (Alpelisib)

    T-last, ss was defined as the time to reach last observed plasma concentration of alpelisib at steady state.

    Time frame: Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  18. Plasma Trough Concentration at Steady State (Ctrough, ss) of LGX818 (Encorafenib)

    Ctrough, ss was defined as plasma trough concentration of encorafenib at steady state.

    Time frame: Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  19. Plasma Trough Concentration at Steady State (Ctrough, ss) of BYL719 (Alpelisib)

    Ctrough, ss was defined as plasma trough concentration of alpelisib at steady state.

    Time frame: Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose

  20. Overall Survival (OS)

    OS was defined as the time (in months) from the date of randomization or date of start of treatment to the date of death due to any cause or data censoring date, whichever occurred first. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.

    Time frame: From the date of randomization or date of start of treatment to the date of death due to any cause or data censoring date, whichever occurred first (up to 43 months)

  21. Overall Response Rate (ORR)

    Overall response rate as assessed by the investigator per RECIST v1.1, was defined as percentage of participants with a best overall response of complete response (CR) or partial response (PR), were recorded from date of randomization or date of start of treatment until date of first documentation of progressive disease (PD) or death due to any cause. CR was defined as complete disappearance of all target and non-nodal target lesions, and sustained for at least 4 weeks apart before progression. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR defined as at least 30 percent (%) decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Only confirmed CR and PR are counted (those confirmed at least 4 weeks).

    Time frame: From date of randomization or date of start of treatment until date of first documentation of PD or death due to any cause (maximum up to 43 months)

  22. Duration of Response (DOR)

    DOR: Time between date of the first documented response (CR or PR) and the date of first documented PD or death due to underlying cancer. If PD or death due to underlying cancer not occurred, then participant was censored at the date of last tumor assessment other than unknown. DOR was calculated for responders (confirmed) only. CR: Disappearance of all target, non-target lesions sustained for \>=4 weeks and any pathological lymph nodes reduced in short axis to \<10mm. PR: \>=30% decrease in sum of diameters of target lesions, taking as reference baseline sum of diameter. PD for target lesions: At least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study treatment, with absolute increase of \>=5 mm, or appearance of \>=1 new lesions. PD for non-target lesions: Unequivocal progression of pre-existing lesions/increase in overall tumor burden leading to discontinuation of therapy or appearance of new unequivocal malignant lesion.

    Time frame: From the first documentation of OR (confirmed CR or PR) to first documentation of PD/death due to any cause or censoring date, whichever occurred first (up to 43 months)

  23. Time to Response (TTR)

    TTR as assessed by investigator according to RECIST v1.1, was defined as the time (in months) from date of randomization or date of start of treatment until first documented response (CR or PR) or data censoring date, whichever occurred first. CR was defined as complete disappearance of all target and non-target lesions sustained for at least 4 weeks apart before progression. Any pathological lymph nodes (whether target or non-target) reduced in short axis to \<10 mm. PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants who did not achieve a confirmed PR or CR, were censored at last adequate tumor assessment date when they did not progress (including deaths not due to underlying disease) or at maximum follow-up (from study start to study end date) when participant had an event for progression-free survival.

    Time frame: From the date of randomization or date of start of treatment until first documented response (CR or PR) or data censoring date, whichever occurred first (maximum up to 43 months)

  24. Phase 1b: Progression Free Survival (PFS)

    PFS was defined as the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. Participants who did not progress per RECIST v1.1, were not known to have died prior to the data cut-off, or received any further anticancer therapy were censored at the date of last adequate tumor assessment or the anticancer therapy date, whichever was earlier.

    Time frame: From date of start of treatment to the date of event defined as the first documented progression or death due to any cause, censored date, whichever occurred first (maximum up to 43 months)

  25. Phase 2: Number of Participants With Any Variant in Gene Status at Baseline

    Gene alterations/expression relevant to the RAF/MEK/ERK (proto-oncogene serine/threonine-protein kinase/ mitogen-activated ERK kinase/ extracellular signal-regulated kinases) and EGFR/PI3K/AKT (epidermal growth factor receptor/ phosphatidylinositol 3-kinase/ protein kinase B) pathways in tumor tissue, baseline molecular status (mutation/amplification/expression) in tumor tissue of potential predictive markers of tumor response or resistance i.e. BRAF (v-raf murine sarcoma viral oncogene homolog B1), HRAS (harvey rat sarcoma protein), KRAS (V-Ki-ras2 kirsten rat sarcoma viral oncogene homolog B1), NRAS (neuroblastoma RAS viral oncogene homolog), PTEN (phosphatase and tensin homolog), PIK3CA (phosphatidylinositol 3-kinase gene), MAP2K1 (mitogen-activated protein kinase 1), MAP2K2 (mitogen-activated protein kinase 2), ARAF, c-MET, RAF1, EGFR was analyzed.

    Time frame: Baseline (Day 1)

07

Results

Posted Jun 23, 2021

Participant flow

Participant flow — Overall Study
MilestonePhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Started2798381075052
Completed0000000001
Not completed2798381075051
Withdrew: Adverse event0012010143
Withdrew: Death0100000033
Withdrew: Participant/guardian decision0010000022
Withdrew: Physician decision0020000011
Withdrew: Lack of efficacy2656371063942
Withdrew: Progressive disease0000000010

Outcome measures

PrimaryPhase 1b: Number of Participants With Incidence of Dose Limiting Toxicities (DLTs): Cycle 1

DLTs were defined as an adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first 28 days of treatment and meets any of the criteria included blood and lymphatic system disorders, investigations (blood, renal, hepatic, metabolic), skin and subcutaneous tissue disorders: rash, HFSR (hand foot skin reaction) and/or photosensitivity, metabolism and nutrition disorders: hyperglycemia, gastrointestinal disorders, cardiac disorders, vascular disorders, general disorders and administration site conditions, tumor lysis syndrome, ophthalmologic and other adverse events: study drug-related fever, alkaline phosphatase elevation.

Time frame:
Cycle 1: Day 1 to Day 28
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Incidence of Dose Limiting Toxicities (DLTs): Cycle 1
ParticipantsPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab
Phase 1b: Number of Participants With Incidence of Dose Limiting Toxicities (DLTs): Cycle 101110011
PrimaryPhase 2: Progression Free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause. Participants who did not progress per RECIST (Response Evaluation Criteria in Solid Tumors) version (v) 1.1, were not known to have died prior to the data cut-off, or received any further anticancer therapy were censored at the date of last adequate tumor assessment or the anticancer therapy date, whichever was earlier.

Time frame:
From the date of randomization until the first documentation of disease progression or death due to any cause, censored date, whichever occurred first (maximum up to 43 months)
Reported as:
Median · months
Phase 2: Progression Free Survival (PFS)
monthsPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Phase 2: Progression Free Survival (PFS)4.2 (3.0 to 5.1)4.9 (4.0 to 7.1)
SecondaryNumber of Participants With Treatment - Emergent Adverse Events of Grade 3 or 4 Severity Based on National Cancer Institute of Common Terminology Criteria (NCI-CTCAE), Version 4.0

An AE was any untoward medical occurrence attributed to study drug in participants who received study drug. As per NCI-CTCAE v4.0, Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to study drug. Treatment-emergent AEs are between first dose of study drug and up to 30 days after last dose of study drug, that were absent before treatment or that worsened relative to pretreatment state. Number of participants with any Grade 3 or 4 treatment-emergent AE were reported in this outcome measure.

Time frame:
From screening up to 30 days after the last dose of study treatment (for a maximum duration of 43 months, approximately)
Reported as:
Count of participants · Participants
Number of Participants With Treatment - Emergent Adverse Events of Grade 3 or 4 Severity Based on National Cancer Institute of Common Terminology Criteria (NCI-CTCAE), Version 4.0
ParticipantsPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Number of Participants With Treatment - Emergent Adverse Events of Grade 3 or 4 Severity Based on National Cancer Institute of Common Terminology Criteria (NCI-CTCAE), Version 4.0246735763343
SecondaryApparent Total Plasma Clearance (CL/F) of LGX818 (Encorafenib)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Mean · liter per hour
Apparent Total Plasma Clearance (CL/F) of LGX818 (Encorafenib)
liter per hourPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Apparent Total Plasma Clearance (CL/F) of LGX818 (Encorafenib)16.8 ± 3.6011.7 ± 6.1012.1 ± 5.9512.3 ± 4.967.69 ± 3.1314.2 ± 5.7514.1 ± 3.6517.8 ± 17.413.1 ± 5.0710.9 ± 5.70
SecondaryApparent Total Plasma Clearance at Steady State (CL/F, ss) of LGX818 (Encorafenib)

Clearance of a drug at steady state is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Mean · liter per hour
Apparent Total Plasma Clearance at Steady State (CL/F, ss) of LGX818 (Encorafenib)
liter per hourPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Cycle 1 Day 8————17.0 ± 3.4224.4 ± 18.315.4 ± 4.2522.4 ± 17.7——
Cycle 2 Day 113.9 ± 4.7231.1 ± 11.931.6 ± 2.1930.5 ± 12.332.6 ± 6.8820.2 ± 7.9122.7 ± 5.6838.4 ± 16.428.2 ± 8.9723.3 ± 11.6
SecondaryApparent Total Plasma Clearance (CL/F) of BYL719 (Alpelisib)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Mean · liter per hour
Apparent Total Plasma Clearance (CL/F) of BYL719 (Alpelisib)
liter per hourPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Apparent Total Plasma Clearance (CL/F) of BYL719 (Alpelisib)12.7 ± 2.0312.1 ± 3.9611.6 ± 1.8511.7 ± 5.3815.6 ± 9.61
SecondaryApparent Total Plasma Clearance at Steady State (CL/F, ss) of BYL719 (Alpelisib)

Clearance of a drug at steady state is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Mean · liter per hour
Apparent Total Plasma Clearance at Steady State (CL/F, ss) of BYL719 (Alpelisib)
liter per hourPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Cycle 1 Day 816.5 ± 5.9613.2 ± 2.2913.7 ± 7.2011.6 ± 6.05—
Cycle 2 Day 118.3 ± 0.79410.3 ± 1.2312.5 ± 1.6019.0 ± 6.5117.9 ± 10.5
SecondaryApparent Terminal Volume of Distribution (Vz/F) of LGX818 (Encorafenib)

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Mean · liter
Apparent Terminal Volume of Distribution (Vz/F) of LGX818 (Encorafenib)
literPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Apparent Terminal Volume of Distribution (Vz/F) of LGX818 (Encorafenib)104 ± 28.360.3 ± 25.862.8 ± 31.857.2 ± 29.649.2 ± 12.475.7 ± 31.664.6 ± 20.660.7 ± 44.063.5 ± 29.980.9 ± 93.9
SecondaryApparent Terminal Volume of Distribution at Steady State (Vz/F, ss) of LGX818 (Encorafenib)

Volume of distribution at steady state is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F, ss) is influenced by the fraction absorbed.

Time frame:
Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Mean · liter
Apparent Terminal Volume of Distribution at Steady State (Vz/F, ss) of LGX818 (Encorafenib)
literPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Cycle 1 Day 8————78.4 ± 13.098.2 ± 84.578.6 ± 26.288.8 ± 53.6——
Cycle 2 Day 166.8 ± 13.7131 ± 45.8110 ± 41.1142 ± 84.5137 ± 32.991.6 ± 41.4102 ± 39.9187 ± 89.5117 ± 37.6105 ± 42.2
SecondaryApparent Terminal Volume of Distribution (Vz/F) of BYL719 (Alpelisib)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Mean · liter
Apparent Terminal Volume of Distribution (Vz/F) of BYL719 (Alpelisib)
literPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Apparent Terminal Volume of Distribution (Vz/F) of BYL719 (Alpelisib)112 ± 22.0104 ± 31.0105 ± 34.3106 ± 78.6123 ± 50.7
SecondaryApparent Terminal Volume of Distribution at Steady State (Vz/F, ss) of BYL719 (Alpelisib)

Volume of distribution at steady state was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F, ss) is influenced by the fraction absorbed.

Time frame:
Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Mean · liter
Apparent Terminal Volume of Distribution at Steady State (Vz/F, ss) of BYL719 (Alpelisib)
literPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Cycle 1 Day 8110 ± 40.797.0 ± 20.6105 ± 30.282.5 ± 18.8—
Cycle 2 Day 1138 ± 20.775.4 ± 11.2104 ± 10.7144 ± 44.5149 ± 100
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of LGX818 (Encorafenib)

Tmax was defined as the time to reach maximum observed plasma concentration of encorafenib.

Time frame:
Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Median · hour
Time to Reach Maximum Observed Plasma Concentration (Tmax) of LGX818 (Encorafenib)
hourPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Time to Reach Maximum Observed Plasma Concentration (Tmax) of LGX818 (Encorafenib)2.00 (1.98 to 2.02)1.99 (0.97 to 2.05)2.03 (1.00 to 4.00)2.17 (1.00 to 5.97)1.00 (0.98 to 1.98)2.02 (1.00 to 4.02)2.00 (0.87 to 5.95)3.87 (1.50 to 4.13)2.00 (0.93 to 6.12)2.03 (0.50 to 8.00)
SecondaryTime to Reach Maximum Plasma Concentration at Steady State (Tmax, ss) of LGX818 (Encorafenib)

Tmax, ss was defined as the time to reach maximum observed plasma concentration of LGX818 (encorafenib) at steady state.

Time frame:
Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Median · hour
Time to Reach Maximum Plasma Concentration at Steady State (Tmax, ss) of LGX818 (Encorafenib)
hourPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Cycle 1 Day 8————0.98 (0.75 to 4.00)1.98 (1.00 to 3.98)2.00 (1.12 to 4.02)3.92 (0.50 to 4.08)——
Cycle 2 Day 11.51 (1.00 to 2.02)2.00 (1.00 to 4.03)1.98 (0.97 to 4.00)1.98 (1.05 to 2.05)2.00 (1.00 to 2.02)2.02 (1.05 to 6.00)3.00 (1.92 to 7.98)2.27 (2.07 to 3.97)1.15 (0.98 to 5.93)2.00 (1.88 to 6.00)
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of BYL719 (Alpelisib)

Tmax was defined as the time to reach maximum observed plasma concentration of alpelisib.

Time frame:
Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Median · hour
Time to Reach Maximum Observed Plasma Concentration (Tmax) of BYL719 (Alpelisib)
hourPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Time to Reach Maximum Observed Plasma Concentration (Tmax) of BYL719 (Alpelisib)1.98 (0.98 to 2.00)3.97 (1.93 to 6.00)2.00 (0.87 to 5.95)2.10 (1.50 to 4.50)2.05 (1.92 to 8.00)
SecondaryTime to Reach Maximum Plasma Concentration at Steady State (Tmax, ss) of BYL719 (Alpelisib)

Tmax, ss was defined as the time to reach maximum observed plasma concentration of BYL719 (alpelisib) at steady state.

Time frame:
Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Median · hour
Time to Reach Maximum Plasma Concentration at Steady State (Tmax, ss) of BYL719 (Alpelisib)
hourPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Cycle 1 Day 81.97 (1.00 to 4.00)3.99 (1.00 to 7.97)2.15 (1.12 to 4.02)4.07 (0.00 to 4.10)—
Cycle 2 Day 12.02 (1.00 to 4.00)4.00 (1.05 to 6.00)3.93 (2.00 to 5.98)4.03 (3.97 to 8.00)2.02 (1.00 to 6.00)
SecondaryTime of Last Observed Plasma Concentration (T-last) of LGX818 (Encorafenib)

T-last was defined as the time to reach last observed plasma concentration of encorafenib.

Time frame:
Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Median · hour
Time of Last Observed Plasma Concentration (T-last) of LGX818 (Encorafenib)
hourPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Time of Last Observed Plasma Concentration (T-last) of LGX818 (Encorafenib)23.98 (23.98 to 23.98)23.69 (8.00 to 24.00)24.03 (22.33 to 24.83)23.58 (8.80 to 24.13)23.00 (22.52 to 24.30)23.06 (7.97 to 24.22)22.02 (8.47 to 24.37)23.87 (8.23 to 25.92)23.85 (8.00 to 24.25)23.50 (5.38 to 24.50)
SecondaryTime of Last Observed Plasma Concentration at Steady State (T-last, ss) of LGX818 (Encorafenib)

T-last, ss was defined as the time to reach last observed plasma concentration of encorafenib at steady state.

Time frame:
Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Median · hour
Time of Last Observed Plasma Concentration at Steady State (T-last, ss) of LGX818 (Encorafenib)
hourPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Cycle 1 Day 8————23.78 (23.75 to 23.92)23.36 (7.58 to 23.98)23.92 (23.48 to 23.97)23.87 (21.83 to 23.95)——
Cycle 2 Day 123.89 (23.88 to 23.90)22.13 (7.30 to 23.85)14.05 (6.00 to 24.67)23.45 (6.00 to 23.98)23.97 (7.25 to 24.20)23.08 (8.00 to 23.98)23.94 (7.00 to 24.38)23.42 (22.08 to 23.58)23.80 (8.07 to 24.17)23.42 (8.00 to 24.48)
SecondaryTime of Last Observed Plasma Concentration (T-last) of BYL719 (Alpelisib)

T-last was defined as the time to reach last observed plasma concentration of alpelisib.

Time frame:
Cycle 1 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Median · hour
Time of Last Observed Plasma Concentration (T-last) of BYL719 (Alpelisib)
hourPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Time of Last Observed Plasma Concentration (T-last) of BYL719 (Alpelisib)23.00 (22.52 to 24.30)23.06 (7.97 to 24.22)22.76 (8.47 to 24.37)23.87 (8.23 to 25.92)23.17 (7.92 to 24.50)
SecondaryTime of Last Observed Plasma Concentration at Steady State (T-last, ss) of BYL719 (Alpelisib)

T-last, ss was defined as the time to reach last observed plasma concentration of alpelisib at steady state.

Time frame:
Cycle 1 Day 8, Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Median · hour
Time of Last Observed Plasma Concentration at Steady State (T-last, ss) of BYL719 (Alpelisib)
hourPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Cycle 1 Day 823.78 (23.75 to 23.92)23.36 (7.58 to 23.98)23.87 (7.75 to 23.97)23.87 (21.83 to 23.95)—
Cycle 2 Day 123.97 (7.25 to 24.20)23.08 (8.00 to 23.98)23.94 (7.00 to 24.38)23.47 (22.08 to 23.58)23.77 (7.00 to 25.50)
SecondaryPlasma Trough Concentration at Steady State (Ctrough, ss) of LGX818 (Encorafenib)

Ctrough, ss was defined as plasma trough concentration of encorafenib at steady state.

Time frame:
Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Mean · nanogram per milliliter
Plasma Trough Concentration at Steady State (Ctrough, ss) of LGX818 (Encorafenib)
nanogram per milliliterPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Plasma Trough Concentration at Steady State (Ctrough, ss) of LGX818 (Encorafenib)9.87 ± 6.6920.5 ± 28.015.7 ± 22.020.6 ± 18.47.69 ± 1.7610.4 ± 5.0526.5 ± 31.429.2 ± NA9.24 ± 5.1915.0 ± 17.8
SecondaryPlasma Trough Concentration at Steady State (Ctrough, ss) of BYL719 (Alpelisib)

Ctrough, ss was defined as plasma trough concentration of alpelisib at steady state.

Time frame:
Cycle 2 Day 1: Pre-dose, 0.5, 1, 2, 4, 6, 8 and 24 +/- 2 hours post-dose
Reported as:
Mean · nanogram per milliliter
Plasma Trough Concentration at Steady State (Ctrough, ss) of BYL719 (Alpelisib)
nanogram per milliliterPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Plasma Trough Concentration at Steady State (Ctrough, ss) of BYL719 (Alpelisib)36.7 ± 21.0108 ± 41.1283 ± 15666.0 ± NA141 ± 76.5
SecondaryOverall Survival (OS)

OS was defined as the time (in months) from the date of randomization or date of start of treatment to the date of death due to any cause or data censoring date, whichever occurred first. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.

Time frame:
From the date of randomization or date of start of treatment to the date of death due to any cause or data censoring date, whichever occurred first (up to 43 months)
Reported as:
Median · months
Overall Survival (OS)
monthsPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Overall Survival (OS)15.0 (14.8 to 15.2)5.4 (1.2 to 7.8)NA (2.9 to NA)16.6 (3.9 to 23.5)6.6 (5.0 to NA)8.7 (3.8 to 27.1)9.8 (3.7 to 25.2)NA (5.3 to NA)9.3 (5.8 to 15.6)8.5 (6.1 to 15.2)
SecondaryOverall Response Rate (ORR)

Overall response rate as assessed by the investigator per RECIST v1.1, was defined as percentage of participants with a best overall response of complete response (CR) or partial response (PR), were recorded from date of randomization or date of start of treatment until date of first documentation of progressive disease (PD) or death due to any cause. CR was defined as complete disappearance of all target and non-nodal target lesions, and sustained for at least 4 weeks apart before progression. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeter (mm). PR defined as at least 30 percent (%) decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Only confirmed CR and PR are counted (those confirmed at least 4 weeks).

Time frame:
From date of randomization or date of start of treatment until date of first documentation of PD or death due to any cause (maximum up to 43 months)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Overall Response Rate (ORR)50.0 (1.3 to 98.7)14.3 (0.4 to 57.9)11.1 (0.3 to 48.2)25.0 (3.2 to 65.1)33.3 (0.8 to 90.6)25.0 (3.2 to 65.1)20.0 (2.5 to 55.6)0 (0.0 to 41.0)24.0 (13.1 to 38.2)26.9 (15.6 to 41.0)
SecondaryDuration of Response (DOR)

DOR: Time between date of the first documented response (CR or PR) and the date of first documented PD or death due to underlying cancer. If PD or death due to underlying cancer not occurred, then participant was censored at the date of last tumor assessment other than unknown. DOR was calculated for responders (confirmed) only. CR: Disappearance of all target, non-target lesions sustained for \>=4 weeks and any pathological lymph nodes reduced in short axis to \<10mm. PR: \>=30% decrease in sum of diameters of target lesions, taking as reference baseline sum of diameter. PD for target lesions: At least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study treatment, with absolute increase of \>=5 mm, or appearance of \>=1 new lesions. PD for non-target lesions: Unequivocal progression of pre-existing lesions/increase in overall tumor burden leading to discontinuation of therapy or appearance of new unequivocal malignant lesion.

Time frame:
From the first documentation of OR (confirmed CR or PR) to first documentation of PD/death due to any cause or censoring date, whichever occurred first (up to 43 months)
Reported as:
Median · months
Duration of Response (DOR)
monthsPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Duration of Response (DOR)10.6 (NA to NA)2.3 (NA to NA)21.7 (NA to NA)8.1 (5.4 to 10.9)3.9 (NA to NA)3.6 (2.8 to 4.4)3.3 (2.8 to 3.8)—5.6 (2.0 to NA)5.3 (2.7 to 10.8)
SecondaryTime to Response (TTR)

TTR as assessed by investigator according to RECIST v1.1, was defined as the time (in months) from date of randomization or date of start of treatment until first documented response (CR or PR) or data censoring date, whichever occurred first. CR was defined as complete disappearance of all target and non-target lesions sustained for at least 4 weeks apart before progression. Any pathological lymph nodes (whether target or non-target) reduced in short axis to \<10 mm. PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants who did not achieve a confirmed PR or CR, were censored at last adequate tumor assessment date when they did not progress (including deaths not due to underlying disease) or at maximum follow-up (from study start to study end date) when participant had an event for progression-free survival.

Time frame:
From the date of randomization or date of start of treatment until first documented response (CR or PR) or data censoring date, whichever occurred first (maximum up to 43 months)
Reported as:
Median · months
Time to Response (TTR)
monthsPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Time to Response (TTR)2.8 (NA to NA)1.4 (NA to NA)3.9 (NA to NA)4.0 (1.4 to 6.7)1.5 (NA to NA)3.5 (1.4 to 5.6)2.0 (1.4 to 2.5)—1.7 (1.2 to 7.7)1.5 (1.4 to 1.7)
SecondaryPhase 1b: Progression Free Survival (PFS)

PFS was defined as the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. Participants who did not progress per RECIST v1.1, were not known to have died prior to the data cut-off, or received any further anticancer therapy were censored at the date of last adequate tumor assessment or the anticancer therapy date, whichever was earlier.

Time frame:
From date of start of treatment to the date of event defined as the first documented progression or death due to any cause, censored date, whichever occurred first (maximum up to 43 months)
Reported as:
Median · months
Phase 1b: Progression Free Survival (PFS)
monthsPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab
Phase 1b: Progression Free Survival (PFS)12.0 (10.6 to 13.4)3.7 (1.2 to 4.1)2.8 (1.3 to 4.3)12.0 (1.8 to 12.3)5.4 (4.4 to 9.1)4.3 (3.8 to 13.6)4.1 (1.7 to 5.8)4.2 (2.9 to 12.3)
SecondaryPhase 2: Number of Participants With Any Variant in Gene Status at Baseline

Gene alterations/expression relevant to the RAF/MEK/ERK (proto-oncogene serine/threonine-protein kinase/ mitogen-activated ERK kinase/ extracellular signal-regulated kinases) and EGFR/PI3K/AKT (epidermal growth factor receptor/ phosphatidylinositol 3-kinase/ protein kinase B) pathways in tumor tissue, baseline molecular status (mutation/amplification/expression) in tumor tissue of potential predictive markers of tumor response or resistance i.e. BRAF (v-raf murine sarcoma viral oncogene homolog B1), HRAS (harvey rat sarcoma protein), KRAS (V-Ki-ras2 kirsten rat sarcoma viral oncogene homolog B1), NRAS (neuroblastoma RAS viral oncogene homolog), PTEN (phosphatase and tensin homolog), PIK3CA (phosphatidylinositol 3-kinase gene), MAP2K1 (mitogen-activated protein kinase 1), MAP2K2 (mitogen-activated protein kinase 2), ARAF, c-MET, RAF1, EGFR was analyzed.

Time frame:
Baseline (Day 1)
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With Any Variant in Gene Status at Baseline
ParticipantsPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
Phase 2: Number of Participants With Any Variant in Gene Status at Baseline3034

Adverse events

Collected over From screening up to 30 days after the last dose of study treatment (maximum up to 43 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b: LGX818 100 mg + Cetuximab—2/2 (100%)2/2 (100%)
Phase 1b: LGX818 200 mg + Cetuximab—5/7 (71.4%)7/7 (100%)
Phase 1b: LGX818 400 mg + Cetuximab—6/9 (66.7%)9/9 (100%)
Phase 1b: LGX818 450 mg + Cetuximab—6/8 (75%)8/8 (100%)
Phase 1b: LGX818 200 mg + BYL719 100 mg + Cetuximab—2/3 (66.7%)3/3 (100%)
Phase 1b: LGX818 200 mg + BYL719 200 mg + Cetuximab—5/8 (62.5%)8/8 (100%)
Phase 1b: LGX818 200 mg + BYL719 300 mg + Cetuximab—6/10 (60%)10/10 (100%)
Phase 1b: LGX818 300 mg + BYL719 200 mg + Cetuximab—4/7 (57.1%)7/7 (100%)
Phase 2: LGX818 200 mg + Cetuximab—25/50 (50%)50/50 (100%)
Phase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab—33/52 (63.5%)52/52 (100%)
Most frequent serious events
Showing 10 of 110
Most frequent serious events
EventPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
PneumoniaInfections and infestations1/21/71/90/80/30/80/101/72/501/52
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/20/71/90/80/30/80/100/70/500/52
Abdominal painGastrointestinal disorders0/21/71/93/80/31/82/100/75/505/52
Blood bilirubin increasedInvestigations0/20/71/91/81/30/80/100/70/500/52
Deep vein thrombosisVascular disorders0/20/70/90/81/30/80/100/70/500/52
IleusGastrointestinal disorders0/20/70/92/80/30/82/100/72/501/52
VomitingGastrointestinal disorders0/20/71/90/80/32/80/100/72/503/52
NauseaGastrointestinal disorders0/20/70/90/80/32/80/100/72/502/52
Cardiac arrestCardiac disorders0/21/70/90/80/30/80/100/71/500/52
Cardiac failure congestiveCardiac disorders0/21/70/90/80/30/80/100/71/500/52
Most frequent other events
Showing 10 of 460
Most frequent other events
EventPhase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + Cetuximab
NauseaGastrointestinal disorders2/21/71/94/80/34/88/105/723/5030/52
FatigueGeneral disorders2/22/75/95/81/32/86/103/725/5027/52
HallucinationPsychiatric disorders2/20/70/90/80/30/80/100/70/500/52
DiarrhoeaGastrointestinal disorders0/20/73/94/80/37/85/105/714/5029/52
VomitingGastrointestinal disorders1/22/75/94/80/34/87/103/717/5025/52
Weight decreasedInvestigations1/22/71/93/81/35/83/102/79/5019/52
Lipase increasedInvestigations0/21/71/90/80/31/81/104/716/507/52
Decreased appetiteMetabolism and nutrition disorders1/22/72/92/81/32/81/104/716/5019/52
HyperglycaemiaMetabolism and nutrition disorders0/21/70/91/81/32/84/104/75/5018/52
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/20/70/91/81/30/82/104/71/506/52

Baseline characteristics

Age, Customized
Age, Customized(Participants)Phase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + CetuximabTotal
<65 years147524863238107
>=65 years13231421181449
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b: LGX818 100 mg + CetuximabPhase 1b: LGX818 200 mg + CetuximabPhase 1b: LGX818 400 mg + CetuximabPhase 1b: LGX818 450 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 100 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 200 mg + CetuximabPhase 1b: LGX818 200 mg + BYL719 300 mg + CetuximabPhase 1b: LGX818 300 mg + BYL719 200 mg + CetuximabPhase 2: LGX818 200 mg + CetuximabPhase 2: LGX818 200 mg + BYL719 300 mg + CetuximabTotal
Female23641575362796
Male04342332142560
08

Study locations

52 sites
  • Keck Hospital of USC
    Los Angeles, California 90033, United States
  • LAC&USC Medical Center
    Los Angeles, California 90033, United States
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
  • UCLA University of California Los Angeles
    Los Angeles, California 90095, United States
  • Westwood Bowyer Clinic, Peter Morton Medical Building
    Los Angeles, California 90095, United States
  • UCLA Hematology Oncology
    Santa Monica, California 90404, United States
  • UCLA Santa Monica Medical Center & Orthopaedic Hospital
    Santa Monica, California 90404, United States
  • Smilow Cancer Hospital at Yale-New Haven
    New Haven, Connecticut 06510, United States
  • Yale University
    New Haven, Connecticut 06520, United States
  • Smilow Cancer Hospital Care Center at North Haven
    North Haven, Connecticut 06473, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114-2620, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10017-6706, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10022, United States
  • Tennessee Oncology, PLLC
    Dickson, Tennessee 37055, United States
  • Tennessee Oncology, PLLC
    Franklin, Tennessee 37067, United States
  • Tennessee Oncology, PLLC
    Gallatin, Tennessee 37066, United States
  • Tennessee Oncology, PLLC
    Hermitage, Tennessee 37076, United States
  • Tennessee Oncology, PLLC
    Lebanon, Tennessee 37909, United States
  • Tennessee Oncology, PLLC
    Murfreesboro, Tennessee 37129, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37205, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37207, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37211, United States
  • Tennessee Oncology, PLLC
    Shelbyville, Tennessee 37160, United States
  • Tennessee Oncology, PLLC
    Smyrna, Tennessee 37167, United States
  • University of Utah - Huntsman Cancer Institute - PPDS
    Salt Lake City, Utah 84112-5550, United States
  • Huntsman Cancer Hospital
    Salt Lake City, Utah 84112, United States
  • Redwood Health Center - ARUP Lab Draw Location
    Salt Lake City, Utah 84119, United States
  • John A Moran Eye Center
    Salt Lake City, Utah 84132, United States
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • UZ Gasthuisberg
    Leuven, Vlaams Brabant 3000, Belgium
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • Sir Mortimer B. Davis Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque
    Montpellier, 34298, France
  • EDOG - Institut Claudius Regaud - PPDS
    Toulouse, 31052, France
  • University Hospital of Koln
    Köln, Nordrhein-westfalen 50937, Germany
  • Universitätsklinikum Essen
    Essen, 45147, Germany
  • Ospedaliero Universitaria di Modena Policlinico
    Modena, 41100, Italy
  • Pharmacy of National Cancer Center Hospital East
    Kashiwa, Chiba 277-8577, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
  • Samsung Medical Center - PPDS
    Gangnam-Gu, Seoul Teugbyeolsi 06351, Korea, Republic of
  • Asan Medical Center - PPDS
    Songpa-Gu, Seoul Teugbyeolsi 05505, Korea, Republic of
  • Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
    Amsterdam, Noord-holland 1066 CX, Netherlands
  • Erasmus MC
    Rotterdam, Zuid-holland 3015 CE, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • Oslo Myeloma Center - PPDS
    Oslo, 0379, Norway
  • Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON
    Barcelona, 08035, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28026, Spain
  • Hospital Universitario Virgen del Rocio - PPDS
    Sevilla, 41013, Spain
09

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2012 to primary completion in Oct 2015, 35 months.

Results were first posted in Jun 2021, 5 years 7 months after primary completion. A results delay was requested in Jul 2017.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 35 months is close to that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2012
First posted
Nov 1, 2012
StartActual
Nov 23, 2012
Primary completionActual
Oct 31, 2015
CompletionActual
Feb 12, 2019
Results delay requested
Jul 17, 2017
Results first posted
Jun 23, 2021
Last update
Jun 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01719380
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 1, 2012
Start date
Nov 23, 2012
Primary completion
Oct 31, 2015
Completion
Feb 12, 2019
Results posted
Jun 23, 2021
Last update
Jun 23, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Encorafenib · Cetuximab · Alpelisib

Start the discussion